ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine

Download PDF Copy

May 4 2010

NewsGuard 100/100 Score

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site. The 6-month stability data are on track to support the submission of the New Drug Application (NDA) for Exelbine.

"These results are what we expected and what we expect to see from the 12-month data," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Once we have the 12-month data, we will submit the Exelbine NDA, which we expect will take place in the fourth quarter of this year."

Source:

ADVENTRX Pharmaceuticals, Inc.

Posted in: Drug Trial News

Tags: Cancer, Crohn's Disease, Dry Eye, Manufacturing, New Drug Application, Pharmaceuticals, Vinorelbine

Comments (0)

Download PDF Copy

Suggested Reading

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

SU2C announces grants to support cutting-edge research in a variety of cancers

SU2C announces grants to support cutting-edge research in a variety of cancers

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Urine RNA analysis shows promise for detecting genitourinary diseases

Urine RNA analysis shows promise for detecting genitourinary diseases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Study focuses on COPD progression in younger populations